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Introduction
Hypergl ycemia is prevalent in critical care. [1] [2] [3] [4] Increased counterregulatory hormone secretion stimulates endogenous glucose production and increases effective insulin resistance, 3, 4 elevating equilibrium glucose levels and reducing the amount of glucose that the body can utilize with a given amount of insulin. Nutritional regimes with high glucose content can exacerbate the issue further. [5] [6] [7] [8] [9] [10] Hyperglycemia worsens outcomes, increasing the risk of severe infection, 11 myocardial infarction, 1 and polyneuropathy and multiple-organ failure. 2, 12 Evidence also exists of significant reductions in other therapies with aggressive glycemic control. 2, [13] [14] [15] [16] [17] Van den Berghe et al. 2, 16, 17 and Krinsley 14, 15 reduced intensive care unit (ICU) patient mortality 18-45% for patients with a length of stay greater than 3 days. Both studies also showed significant cost savings per patient. 18, 19 Other studies focused primarily on glucose control are limited in duration or patient numbers and do not extend to mortality end points. [20] [21] [22] [23] [24] [25] All of these studies used ad-hoc sliding scale or titration-based protocols developed primarily by clinical experience (i.e., expert-based control), a typical "one size fits all" solution. They are thus less optimal when faced with the dynamic patient variation typical of critical care. This issue has been illustrated in simulation 26, 27 and clinical analysis. 7, [27] [28] [29] [30] [31] [32] [33] There is also little agreement on what constitutes desirable glycemic performance, [34] [35] [36] particularly with regard to how tight control affects outcome, although evidence is emerging that tighter is better. 37, 38 In contrast, model-based tight glycemic control protocols have been successful in producing consistent control. 28, [39] [40] [41] [42] [43] [44] The general state of model-based glycemic control for critical care has been reviewed, 45 although the field is evolving rapidly. However, almost all such model-based clinical studies have been first trialled using some form of virtual patient or simulator that is typically based on retrospective clinical data, [46] [47] [48] [49] with similar uses in controlling type 1 diabetes. [50] [51] [52] [53] [54] [55] Thus, a significant prerequisite of model-based methods is the availability of clinical data, or other validated virtual patient models, 56, 57 on which to test and develop glycemic control protocols.
Finally, it is often very difficult to compare results. Differences across patient cohorts, condition, and other variables are almost impossible to reasonably normalize or eliminate, making concrete direct comparison of results from different studies or virtual trials infeasible. What is needed is the ability to compare different protocols on the same patient, a task that is most reasonably feasible in virtual or simulated trials. The benchmark data set presented here offers the opportunity to make these comparisons in an open source data set from the ongoing clinical implementation of the SPRINT protocol, which has significantly reduced mortality for a general medical ICU cohort in Christchurch Hospital (New Zealand). 26, 48, [58] [59] [60] 
Methods

Benchmark Patient Cohort
All 20 patients were part of the ongoing SPecialized Relative Insulin and Nutrition Tables (SPRINT) clinical practice change in the Department of Intensive Care Medicine at Christchurch Hospital. The details of SPRINT and its development are well documented from initial virtual trials to pilot study results and correlation of virtual results with clinical results and the end result of this approach to glycemic control. 26, 48, 59, 60 However, main criteria to note for this benchmark data set include the following.
• Entry criteria: random glucose greater than 8 mmol/liter or clinician's choice based on condition, and enteral or parenteral nutrition
• Exclusion criteria: none
• Length of stay greater than 5 days on SPRINT Specific patient data are presented in 26 Therefore, time spent on SPRINT may be shorter than the total ICU stay in Table 1 .
SPRINT and Treatment Data
SPRINT uses data from current and prior glucose measurements and prior insulin and nutrition inputs over a prior a Hospital outcomes include "Home" for patients who returned home and "CRN" for those who went to chronic nursing care centers. ICU survivors go to less acute wards, denoted "Ward." Mortalities are shaded. These data can also be compared to full SPRINT cohort data presented elsewhere.60 b COAD, chronic obstructive airways disease. c AAA, abdominal aortic aneurysm. clinical needs. These adjustments are seen in less than 0.3% of the total hours. Some patients received parenteral nutrition with 12.5% dextrose for a short part of their stay for clinical reasons, which is listed separately in glucose infusion data. Additionally, there will be some hours without nutritional input, usually before or after surgery or due to other complications, during which time SPRINT only utilizes the insulin wheel. 26, 59 Sensor and dosing errors can be problematic in glycemic control. In this case, there were no errors in dose or timing reported for the nutrition and insulin inputs given. All timings were rounded to the nearest hour given based on the format of the clinical data sheets used in Christchurch Hospital. Data for nutrition and insulin were thus obtained directly from what the clinical staff recorded in the patient records while using SPRINT and were assumed to occur on or near the hour recorded. Hence, no further error was assumed for these values when used in modeling. However, the glucose measurements were all made using bedside Glucocard™ test strip II glucose testing kits (Arkray, Inc., Kyoto, Japan), which have a reported error of 7-10% depending on glycemic level, and occasional much larger unexplained errors. 48 These sensor errors were thus embedded within data provided.
Data Files, Structure, and Units
Data are provided in Microsoft Excel worksheets in a single overall spreadsheet file. Each sheet has data for a single patient, including the basic patient number and data on length of stay. Data can be exported readily from this format to the computational environment of choice (e.g., Matlab or C/C++). Table 2 shows the initial portion of the first patient record (patient 5017) as an exemplar.
The international system of units (SI) (mmol/liter) is given for all data, as well. Note that millimoles per liter and similar SI are used because they were the original units provided by the sensors, and there are thus no conversions or other manipulations placed on data.
In the remainder of this article, where specific values are referenced in millimoles per liter, the equivalent milligrams per deciliter value is given in parentheses immediately following. The tables and figures utilize only millimoles per liter units to match data.
Within the associated Excel spreadsheet for a given patient a series of color codes and notes are used. Pink delineates the start of SPRINT using both insulin and nutrition wheels. Green denotes periods where nutritional inputs were shut off for clinical reasons and only the insulin wheel portion of SPRINT is used. Some very evident periods of noncompliance to the SPRINT protocol by the attending clinical staff at that time are shaded blue, although these changes or deviations may have been clinically related but not specifi ed in the notes. Periods where SPRINT has been stopped are highlighted in yellow with an associated note if it is evident that it was stopped by protocol or for clinical reasons.
Performance Metrics and Statistics
Statistically, all data are presented using lognormal statistics or nonparametric counted values. Normal statistics for glycemic control are often in error because of the skew seen in the distributions with higher outliers and a lower central mode with few, or no, very low values. The main result is that normal distributions can overestimate the mean if applied to lognormal distributions, providing an approximately 64th percentile value, as well as resulting in a much larger standard deviation. 61 In this case, the mean and standard deviation are provided in both formats for comparison and illustration, but lognormal statistics are encouraged for glucose data. Note that for the nutrition and insulin control input interventions given, normal statistics will suffi ce, as they do not possess the same skew in this case. Finally, nonparametric values, such as the median, interquartile range, and 90% confi dence intervals, can also be used to describe data without these issues.
Glycemic control performance is also represented in this article by percentage time in glycemic bands. The bands used here match those of the earlier SPRINT studies and overlap to provide a sense of the distribution shape. The percentage time in band is calculated by measurement value weighted by the time interval between measurements, where SPRINT measured 1-2 hourly based on glycemic stability. 26, 59 Further results, outcomes, and glycemic bands for all SPRINT patients are also available in the literature. 60 Graphically, data are presented in terms of empirical S-shaped cumulative distribution functions derived directly from data. These functions provide the likelihood from 0.0 to 1.0 of glycemic level or occurrence for a given data set where 0.0 is the likelihood of the lowest possible measure and 1.0 is the likelihood of the highest. If lognormal distribution data (mean, standard deviation) derived from the same data were integrated and plotted, they would fi t these empirical cumulative distribution functions.
Finally, all data are presented in both overall and perpatient bases. These metrics thus provide both overall cohort results, as well as showing per-patient differences or variability. This overall set of summaries should provide a complete description of data.
Ethics approval to audit, collect, and present these data was obtained from the South Island Regional Ethics Committee, New Zealand.
Virtual Trials and Applications
The goal of providing this data set is to encourage further research in the fi eld and enable comparisons in virtual trials to the clinical results. Virtual trials can be readily run by the following fundamental steps.
1. Fit glucose, insulin, and nutrition data to a model obtaining the model parameters as desired.
2.
Resimulate the fi tted model with different insulin and/or nutritional inputs based on the control protocol designed to obtain a "virtual trial" blood glucose trajectory.
3. Compare with original data and assess performance for individual patients or the entire cohort as desired.
This broad process is outlined in Figure 1 . In addition, this fundamental process has been employed and validated in other studies 26, [46] [47] [48] 52 and provides a useful means of obtaining an estimate of outcome before clinical testing. Figure 1 . Virtual trial outline as utilized in prior work 26, 48, 57, 62 showing the overall approach and elements for a virtual trial. Note that the model used does not have to be the one shown, as the fi gure is used to show only the basic steps of the approach.
The data may also be used for model validation. Simply, model parameters may be fit to data using any number of methods to determine if a given model can capture the clinical dynamics seen. Additional validation can be obtained via testing forward prediction of blood glucose values for a given intervention in data to ensure that a given model can provide proper trend dynamics in treatment uses for a set of patient or model-specific parameters. Table 3 outlines glycemic control performance for the benchmark cohort for individual patients and selected overall statistics. The results are provided in lognormal statistics with multiplicative (unitless) standard deviations. The overall averages reported for glycemic levels, time in band, insulin, and nutrition are weighted by the patient time for each record. The maximum and minimum Table 3 and the 95% range noted previously. Matching glucose ranges or values from Table 3 on Figure 2 reveal the same results for time in band or 95% confidence intervals. Hence, Figure 2 summarizes overall glycemic data of the cohort. Figure 3 shows same data on a per-patient basis. In this case, each individual curve is that of a single patient. The darker dashed lines show the calculated median patient at each cumulative probability level and the related 90% confidence interval range. The interquartile range lines are not shown for clarity in this smaller cohort. As a check, it is worth noting that the 0.50 or 50th percentile value for the median patient is approximately the same 5.8-mmol/liter (105 mg/dl) value it is for the overall cohort, as expected.
Results
Overall, Figures 2 and 3 show the relatively tight glycemic performance. Comparing the two plots indicates that while individual patients are different, they are primarily shifted rather than crossing by large amounts. Hence, the control is similarly tight per patient versus the entire cohort, as seen in the lognormal standard deviations in Table 3 . Thus, the longer-staying patients in this cohort are, overall, relatively stable in their control.
Discussion
This benchmark problem cohort has been created to mimic the longer-staying general or medical ICU patient cohort seen with SPRINT. 60 These longer-staying patients are the cohort that, in most studies, sees some of the greatest benefit from tight glycemic control in terms of mortality and other outcomes. However, this specific medical ICU cohort may not fully reflect a less critically ill cohort, such as a cardiovascular surgery-focused cohort. Similarly, the distribution is such that it may not Table 3 and the calculated 95% two sigma lognormal range.
BG (mmol/liter) Cumulative Probability Distribution Figure 2 . Empirical cumulative distribution function of measured blood glucose for the entire benchmark cohort. The nonsymmetric tick marks for blood glucose indicate the bounds for the major bands reported in Table 3 and the calculated 95% two sigma lognormal range. represent the more critically ill cohorts found in studies focused strictly on sepsis, for example.
The overall approach of using virtual trials is a datadriven approach based on real patient data. However, it is thus no better or representative than those data. In particular, it would take very large numbers, beyond that of a simple(r) benchmark problem, to show the true range or variability. Hence, this cohort has been limited in size, while still attempting to maximize its ability to represent a major segment of the SPRINT cohort and overall SPRINT cohort behavior. The overall mean, standard deviations, and 90% confidence interval spreads over this cohort are thus well matched to the 384 patient SPRINT cohort's overall results to within 0.1-0.2 mmol/liter (1.3-3.6 mg/dl) in all overall metrics and have a similar distribution as well. Alternatively, it is possible to use emerging stochastic modeling techniques to create equally well-correlated virtual cohorts. 56, 57 In terms of usefulness for designing or analyzing protocols, the virtual patient approach hinges on how well its predicted outcomes match eventual clinical results. With SPRINT, the initial Monte Carlo simulation of approximately 16,000 patient hours on a 19 patient virtual cohort was performed prior to implementing SPRINT clinically. 26 After the first approximately 16,000 clinical measurements (over ~160 patients), results of the virtual and actual trials were compared, with the resulting cumulative distribution functions shown in Figure 4 , which shows that the original simulations and clinical raw data match very well, providing validation of the overall approach in this case. The fitted lognormal distribution to clinical data provides the same result and reinforces the need to use this distribution to represent these data. Figure 4 also contains the SPRINT clinical percentiles for different glycemic bands, which closely match data in Table 3 for this limited benchmark cohort. Finally, Figure 5 shows benchmark raw cumulative distribution versus raw clinical data from Figure 4 . The close match of these two curves graphically indicates the level to which the benchmark cohort matches the total cohort response.
Overall, Figures 4 and 5 provide further reinforcement for two main results. First, the overall virtual trials approach can, in this case at least, provide a good indicator of how a protocol will perform in practice. Second, the benchmark cohort presented, while a very limited subset of all SPRINT patients, closely matches the overall glycemic performance of the larger SPRINT cohort.
Virtual trials also offer the opportunity to test other technologies or approaches. In this case, bolus insulin delivery and measurement were made using glucometers. However, given a fitted patient-specific modeling approach based on benchmark data, there is no limitation to utilize the same measurement or delivery technologies, or timing in subsequent simulation. Thus, enteral versus parenteral feeding could be evaluated in silico in terms of glycemic control, as could technologies such as continuous sensing or different insulin delivery approaches.
A tertiary outcome of presenting this cohort is the different approach to performance metrics. In particular, the use of cumulative distributions and/or overlapping times in glycemic bands provides a clear picture and allows easy comparison across studies. The cumulative distributions can be especially useful in this regard, as time or percentage in any band can be obtained directly Finally, there are limitations to this approach, and there is no replacement for clinical validation. However, virtual trials can offer a great deal of insight into glycemic performance before a protocol is implemented, thus potentially reducing the development time and increasing the likelihood of success. This outcome is significant given the growing number of studies that have had difficulty repeating the earliest results in this field. 23
Limitations and Comments on Clinical Data
One potential limitation would be whether 20 patients are enough for creating a realistic virtual cohort that would provide good results. 26 Hence, given the good correlation in Figure 3 with data from SPRINT and the subset used in this benchmark cohort, it is reasonable to conclude that the data set presented has the data density and size to be suitable for effective virtual trials.
With respect to clinical data itself, there are some limitations. As noted in the data set there are periods of noncompliance to the protocol, periods where clinical imperatives have overridden the protocol. There are also periods where the protocol was stopped. All of these can have a variety of clinical causes based on patient condition at the time and the resulting clinical staff decision making.
More specifically, some patients are off SPRINT for short periods for trips to surgery or other interventions/ therapies outside the unit, including patient movement for magnetic resonance imaging scans. Longer periods off SPRINT are due, in this cohort, to the protocolstopping criterion when the patient is stabilized. Thus, for example, patient 5105 has a 92-hour period off SPRINT. This patient also has an extended period at maximum feed rates that is noncompliant to SPRINT, which is assumed because of specific clinical choices or reasons. Similarly, patient 5069 has five periods off SPRINT ranging from 2 to 24 hours, as this patient had several surgical interventions resulting from their admission because of trauma. These examples, and the others in the set, are typical of ICU data in general and reveal the wide range of potential difficulties and peculiarities faced by any protocol.
However, these issues do not affect data itself nor does it preclude virtual patient cohort development. All data presented include any periods of noncompliance for clinical or other reasons. Thus, the patients chosen are also broadly representative of the best and worst cases in terms of interruptions and compliance to provide a good picture of the clinical problem within data provided.
Conclusions
A benchmark data cohort was presented for glycemic control in critical care, based on clinical results from the ongoing SPRINT protocol trials in Christchurch, New Zealand. Data and its potential applications in model development, model validation, and virtual trial protocol development are provided. The overall performance is summarized using a variety of information-dense metrics that provide a full and clear picture of the overall performance achieved. Finally, this benchmark cohort presented is offered as a means of enabling comparison of model-based protocols on the same cohort, as well as providing data for model development and dynamic and predictive model validation to those research groups with less access.
